Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
The NHS Commissioning Board (Operating Under the Name of NHS England)
2nd Floor Rutland House
Runcorn
WA7 2ES
UK
E-mail: Katie.noonan@nhs.net
NUTS: UK
Internet address(es)
Main address: https://www.england.nhs.uk/
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS National Framework Agreement for Adalimumab Injection
Reference number: CM/PHR/19/5575
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS Framework Agreement for Adalimumab Injection
Offer reference number: CM/PHR/19/5575
Period of framework agreement: 1 April 2020-31 March 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
445 000 000.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UKC
UKD
UKE
UKF
UKG
UKH
UKI
UKJ
UKK
II.2.4) Description of the procurement
NHS Framework Agreement for Adalimumab Injection
Offer reference number: CM/PHR/19/5575
Period of framework agreement: 1 April 2020-31 March 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Products associated with the tender are listed on Document No 5 of the invitation to offer.
There is no restriction on the number of products that bidders can offer for or be awarded.
The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.
The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: n/a
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: n/a
II.2.11) Information about options
Options:
Yes
Description of options:
Whilst we have indicated that lots will not be applicable in II.1.6) a lotting strategy will be implemented for one element of the framework however the lots are not pre-determined.
Please refer to the ITT documents for a description of how this will operate.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2020/S 010-018959
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
06/03/2020
V.2.2) Information about tenders
Number of tenders received: 6
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
AbbVie Ltd
08004972
AbbVie House, Vanwall Road
Berkshire
SL6 4UB
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 445 000 000.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Contract No: CM/PHR/19/5575
Title: NHS National Framework Agreement for Adalimumab Injection
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
06/03/2020
V.2.2) Information about tenders
Number of tenders received: 6
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Amgen Ltd
240 Cambridge Science Park
Cambridgeshire
CB4 0WD
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 445 000 000.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Contract No: CM/PHR/19/5575
Title: NHS National Framework Agreement for Adalimumab Injection
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
06/03/2020
V.2.2) Information about tenders
Number of tenders received: 6
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Biogen Ltd
Biogen, Innovation House, 70 Norden Road
Berkshire
SL6 4AY
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 445 000 000.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: NHS National Framework Agreement for Adalimumab Injection
Contract No: CM/PHR/19/5575
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
06/03/2020
V.2.2) Information about tenders
Number of tenders received: 6
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Fresenius Kabi Ltd
Cestrian Court, Eastgate Way, Manor Park Cheshire
Runcorn
WA7 1NT
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 445 000 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Awarded suppliers:
— AbbVie Ltd,
— Amgen Ltd,
— Biogen Ltd,
— Fresenius Kabi Ltd.
VI.4) Procedures for review
VI.4.1) Review body
The Royal Courts of Justice
London or any of the district registry of the High Court
UK
VI.5) Date of dispatch of this notice
03/04/2020